Jason S.  Kim net worth and biography

Jason Kim Biography and Net Worth

Jason Kim serves as President, Chief Operating Officer of the Company. Mr. Kim joined Private Molecular in February 2010 and served as its President and Chief Financial Officer until the completion of the Merger. From 2009 to 2011, Mr. Kim served as Director, Business and Corporate Development for OSI Pharmaceuticals, Inc. (now Astellas Pharma US, Inc.), an oncology focused biotechnology company. Prior to 2009, Mr. Kim served as an Investment Associate for Domain Associates, LLC, a venture capital firm focused on investments in the biotechnology industry. From 2003 to 2006, Mr. Kim also served as Director, Business Development for ImClone Systems Incorporated (now Eli Lilly and Company), a biotechnology company focused on antibody therapeutics. Mr. Kim received his B.A. in Neuroscience and Behavior from Wesleyan University and an M.B.A. from the Wharton School, University of Pennsylvania.

What is Jason S. Kim's net worth?

The estimated net worth of Jason S. Kim is at least $12,866.56 as of June 28th, 2021. Mr. Kim owns 5,744 shares of Molecular Templates stock worth more than $12,867 as of March 28th. This net worth evaluation does not reflect any other assets that Mr. Kim may own. Additionally, Mr. Kim receives a salary of $639,850.00 as Insider at Molecular Templates. Learn More about Jason S. Kim's net worth.

How old is Jason S. Kim?

Mr. Kim is currently 49 years old. There are 3 older executives and no younger executives at Molecular Templates. The oldest executive at Molecular Templates is Dr. Maurizio Voi M.D., Chief Medical Officer, who is 66 years old. Learn More on Jason S. Kim's age.

What is Jason S. Kim's salary?

As the Insider of Molecular Templates, Inc., Mr. Kim earns $639,850.00 per year. The highest earning executive at Molecular Templates is Dr. Eric E. Poma Ph.D., CEO, Chief Scientific Officer & Director, who commands a salary of $923,340.00 per year. Learn More on Jason S. Kim's salary.

How do I contact Jason S. Kim?

The corporate mailing address for Mr. Kim and other Molecular Templates executives is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. Molecular Templates can also be reached via phone at (512) 869-1555 and via email at [email protected]. Learn More on Jason S. Kim's contact information.

Has Jason S. Kim been buying or selling shares of Molecular Templates?

Jason S. Kim has not been actively trading shares of Molecular Templates in the last ninety days. Most recently, Jason S. Kim sold 184 shares of the business's stock in a transaction on Monday, June 28th. The shares were sold at an average price of $125.40, for a transaction totalling $23,073.60. Following the completion of the sale, the insider now directly owns 5,744 shares of the company's stock, valued at $720,297.60. Learn More on Jason S. Kim's trading history.

Are insiders buying or selling shares of Molecular Templates?

During the last twelve months, Molecular Templates insiders bought shares 1 times. They purchased a total of 283,687 shares worth more than $1,999,993.35. The most recent insider tranaction occured on July, 17th when Major Shareholder Target N V Biotech bought 283,687 shares worth more than $1,999,993.35. Insiders at Molecular Templates own 18.7% of the company. Learn More about insider trades at Molecular Templates.

Information on this page was last updated on 7/17/2023.

Jason S. Kim Insider Trading History at Molecular Templates

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/28/2021Sell184$125.40$23,073.605,744View SEC Filing Icon  
See Full Table

Jason S. Kim Buying and Selling Activity at Molecular Templates

This chart shows Jason S Kim's buying and selling at Molecular Templates by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Molecular Templates Company Overview

Molecular Templates logo
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $2.24
Low: $2.10
High: $2.78

50 Day Range

MA: $3.32
Low: $1.75
High: $4.03

2 Week Range

Now: $2.24
Low: $1.68
High: $9.45

Volume

377,259 shs

Average Volume

32,316 shs

Market Capitalization

$12.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2